Kyntra Bio公布FG-3246联合恩杂鲁胺治疗转移性去势抵抗性前列腺癌的研究者发起1B/2期研究积极数据，将于2026年ASCO GU大会展示

美股速递02-24

Kyntra Bio公司宣布，其FG-3246与恩杂鲁胺联合用药方案针对转移性去势抵抗性前列腺癌患者的临床研究取得积极进展。这项由研究者发起的1B/2期试验数据显示出显著治疗潜力，相关完整数据报告已获选将于2026年美国临床肿瘤学会泌尿生殖系统肿瘤研讨会进行正式发布。

该研究聚焦于晚期前列腺癌治疗领域的前沿探索，通过双药联用策略旨在突破现有治疗方案瓶颈。试验结果不仅验证了联合用药的安全性特征，更展现出令人鼓舞的疗效信号，为转移性去势抵抗性前列腺癌患者提供了新的治疗希望。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1173376495?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-24 06:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173376495","market":"us","top_or_hot":-1,"title":"Kyntra Bio公布FG-3246联合恩杂鲁胺治疗转移性去势抵抗性前列腺癌的研究者发起1B/2期研究积极数据，将于2026年ASCO GU大会展示","media":"美股速递","content":"<p>Kyntra Bio公司宣布，其FG-3246与恩杂鲁胺联合用药方案针对转移性去势抵抗性前列腺癌患者的临床研究取得积极进展。这项由研究者发起的1B/2期试验数据显示出显著治疗潜力，相关完整数据报告已获选将于2026年美国临床肿瘤学会泌尿生殖系统肿瘤研讨会进行正式发布。</p>\n<p>该研究聚焦于晚期前列腺癌治疗领域的前沿探索，通过双药联用策略旨在突破现有治疗方案瓶颈。试验结果不仅验证了联合用药的安全性特征，更展现出令人鼓舞的疗效信号，为转移性去势抵抗性前列腺癌患者提供了新的治疗希望。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kyntra Bio公布FG-3246联合恩杂鲁胺治疗转移性去势抵抗性前列腺癌的研究者发起1B/2期研究积极数据，将于2026年ASCO GU大会展示</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKyntra Bio公布FG-3246联合恩杂鲁胺治疗转移性去势抵抗性前列腺癌的研究者发起1B/2期研究积极数据，将于2026年ASCO GU大会展示\n</h2>\n\n<h4 class=\"meta\">\n\n2026-02-24 06:11 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Kyntra Bio公司宣布，其FG-3246与恩杂鲁胺联合用药方案针对转移性去势抵抗性前列腺癌患者的临床研究取得积极进展。这项由研究者发起的1B/2期试验数据显示出显著治疗潜力，相关完整数据报告已获选将于2026年美国临床肿瘤学会泌尿生殖系统肿瘤研讨会进行正式发布。\n该研究聚焦于晚期前列腺癌治疗领域的前沿探索，通过双药联用策略旨在突破现有治疗方案瓶颈。试验结果不仅验证了联合用药的安全性特征，更...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KYNB","symbol_name":"Kyntra Bio Inc","start_time":0,"source_url":"","article_id":"1173376495","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173376495","pubTimestamp":1771884675,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Kyntra Bio公司宣布，其FG-3246与恩杂鲁胺联合用药方案针对转移性去势抵抗性前列腺癌患者的临床研究取得积极进展。这项由研究者发起的1B/2期试验数据显示出显著治疗潜力，相关完整数据报告已获选将于2026年美国临床肿瘤学会泌尿生殖系统肿瘤研讨会进行正式发布。\n该研究聚焦于晚期前列腺癌治疗领域的前沿探索，通过双药联用策略旨在突破现有治疗方案瓶颈。试验结果不仅验证了联合用药的安全性特征，更展现出令人鼓舞的疗效信号，为转移性去势抵抗性前列腺癌患者提供了新的治疗希望。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"KYNB":"Kyntra Bio Inc","BK4139":"生物科技"},"translate_title":"Kyntra Bio Announces Positive Data from Investigator-Initiated Phase 1B/2 Study of FG-3246 in Combination with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer, to be Presented at ASCO GU 2026","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KYNB":1},"content_text":"Kyntra Bio公司宣布，其FG-3246与恩杂鲁胺联合用药方案针对转移性去势抵抗性前列腺癌患者的临床研究取得积极进展。这项由研究者发起的1B/2期试验数据显示出显著治疗潜力，相关完整数据报告已获选将于2026年美国临床肿瘤学会泌尿生殖系统肿瘤研讨会进行正式发布。\n该研究聚焦于晚期前列腺癌治疗领域的前沿探索，通过双药联用策略旨在突破现有治疗方案瓶颈。试验结果不仅验证了联合用药的安全性特征，更展现出令人鼓舞的疗效信号，为转移性去势抵抗性前列腺癌患者提供了新的治疗希望。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1173376495","isCrawlerRequest":true}